UCB Sells S Asia Established Drugs Business To Dr. Reddy’s
This article was originally published in PharmAsia News
Belgium’s UCB will sell its established products business in India to Dr. Reddy’s Labs – a move it said will help it grow its innovative neurology drugs portfolio. The Indian company expects to gain an edge in areas like respiratory, dermatology and pediatrics.
You may also be interested in...
FDA downgrades Mallinckrodt and Kudco’s methylphenidate generics from AB- to BX-rated. An influx of patient complaints about lack of efficacy spurred an investigation of the products and subsequent revision of the agency’s draft bioequivalence guidelines for the ADHD drug.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.